nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—head and neck cancer	0.651	1	CbGaD
Pomalidomide—CYP1A2—Fluorouracil—head and neck cancer	0.0293	0.297	CbGbCtD
Pomalidomide—ABCB1—Vinblastine—head and neck cancer	0.0237	0.241	CbGbCtD
Pomalidomide—ABCB1—Docetaxel—head and neck cancer	0.0196	0.199	CbGbCtD
Pomalidomide—CYP3A4—Vinblastine—head and neck cancer	0.0142	0.144	CbGbCtD
Pomalidomide—CYP3A4—Docetaxel—head and neck cancer	0.0117	0.119	CbGbCtD
Pomalidomide—Neutropenic sepsis—Fluorouracil—head and neck cancer	0.00799	0.0581	CcSEcCtD
Pomalidomide—Neutropenic sepsis—Docetaxel—head and neck cancer	0.00577	0.042	CcSEcCtD
Pomalidomide—Bronchopneumonia—Docetaxel—head and neck cancer	0.00458	0.0333	CcSEcCtD
Pomalidomide—Thromboembolic event—Docetaxel—head and neck cancer	0.00372	0.027	CcSEcCtD
Pomalidomide—Developmental delay—Fluorouracil—head and neck cancer	0.00365	0.0265	CcSEcCtD
Pomalidomide—Congenital anomaly—Fluorouracil—head and neck cancer	0.00365	0.0265	CcSEcCtD
Pomalidomide—Platelet count decreased—Hydroxyurea—head and neck cancer	0.00324	0.0235	CcSEcCtD
Pomalidomide—Febrile neutropenia—Hydroxyurea—head and neck cancer	0.0032	0.0233	CcSEcCtD
Pomalidomide—Lenalidomide—PTGS2—head and neck cancer	0.00288	0.391	CrCbGaD
Pomalidomide—Thalidomide—CYP1A1—head and neck cancer	0.00276	0.375	CrCbGaD
Pomalidomide—Febrile neutropenia—Fluorouracil—head and neck cancer	0.0023	0.0168	CcSEcCtD
Pomalidomide—Bone pain—Vinblastine—head and neck cancer	0.00221	0.016	CcSEcCtD
Pomalidomide—Lymphopenia—Docetaxel—head and neck cancer	0.00196	0.0142	CcSEcCtD
Pomalidomide—Thalidomide—PTGS2—head and neck cancer	0.00172	0.234	CrCbGaD
Pomalidomide—Febrile neutropenia—Docetaxel—head and neck cancer	0.00166	0.0121	CcSEcCtD
Pomalidomide—Deep vein thrombosis—Docetaxel—head and neck cancer	0.00165	0.012	CcSEcCtD
Pomalidomide—Embolism—Docetaxel—head and neck cancer	0.00156	0.0113	CcSEcCtD
Pomalidomide—Interstitial lung disease—Docetaxel—head and neck cancer	0.00141	0.0103	CcSEcCtD
Pomalidomide—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00131	0.00953	CcSEcCtD
Pomalidomide—Breast disorder—Hydroxyurea—head and neck cancer	0.00126	0.00919	CcSEcCtD
Pomalidomide—Pancytopenia—Vinblastine—head and neck cancer	0.00126	0.00915	CcSEcCtD
Pomalidomide—Sepsis—Fluorouracil—head and neck cancer	0.0012	0.00875	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00116	0.00842	CcSEcCtD
Pomalidomide—Pancytopenia—Hydroxyurea—head and neck cancer	0.00115	0.00835	CcSEcCtD
Pomalidomide—Neutropenia—Hydroxyurea—head and neck cancer	0.00113	0.00822	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.0011	0.008	CcSEcCtD
Pomalidomide—Weight increased—Hydroxyurea—head and neck cancer	0.0011	0.008	CcSEcCtD
Pomalidomide—Infestation NOS—Hydroxyurea—head and neck cancer	0.00108	0.00784	CcSEcCtD
Pomalidomide—Infestation—Hydroxyurea—head and neck cancer	0.00108	0.00784	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00106	0.00768	CcSEcCtD
Pomalidomide—Bone pain—Docetaxel—head and neck cancer	0.00104	0.0076	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00102	0.00741	CcSEcCtD
Pomalidomide—Pulmonary embolism—Docetaxel—head and neck cancer	0.001	0.00728	CcSEcCtD
Pomalidomide—Neuropathy—Docetaxel—head and neck cancer	0.00094	0.00683	CcSEcCtD
Pomalidomide—Dry skin—Fluorouracil—head and neck cancer	0.000923	0.00671	CcSEcCtD
Pomalidomide—Nasopharyngitis—Fluorouracil—head and neck cancer	0.0009	0.00654	CcSEcCtD
Pomalidomide—Muscular weakness—Fluorouracil—head and neck cancer	0.000888	0.00645	CcSEcCtD
Pomalidomide—Angiopathy—Hydroxyurea—head and neck cancer	0.000878	0.00638	CcSEcCtD
Pomalidomide—Sepsis—Docetaxel—head and neck cancer	0.000868	0.00631	CcSEcCtD
Pomalidomide—Chills—Hydroxyurea—head and neck cancer	0.000868	0.00631	CcSEcCtD
Pomalidomide—Anaemia—Vinblastine—head and neck cancer	0.000853	0.00621	CcSEcCtD
Pomalidomide—Vertigo—Vinblastine—head and neck cancer	0.00083	0.00603	CcSEcCtD
Pomalidomide—Leukopenia—Vinblastine—head and neck cancer	0.000827	0.00601	CcSEcCtD
Pomalidomide—Pancytopenia—Fluorouracil—head and neck cancer	0.000826	0.00601	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000809	0.00588	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000801	0.00582	CcSEcCtD
Pomalidomide—Pneumonia—Fluorouracil—head and neck cancer	0.00078	0.00567	CcSEcCtD
Pomalidomide—Anaemia—Hydroxyurea—head and neck cancer	0.000778	0.00566	CcSEcCtD
Pomalidomide—Infestation NOS—Fluorouracil—head and neck cancer	0.000776	0.00564	CcSEcCtD
Pomalidomide—Infestation—Fluorouracil—head and neck cancer	0.000776	0.00564	CcSEcCtD
Pomalidomide—Atrial fibrillation—Docetaxel—head and neck cancer	0.000767	0.00557	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00076	0.00553	CcSEcCtD
Pomalidomide—Urinary tract infection—Fluorouracil—head and neck cancer	0.000754	0.00548	CcSEcCtD
Pomalidomide—Leukopenia—Hydroxyurea—head and neck cancer	0.000754	0.00548	CcSEcCtD
Pomalidomide—Thrombocytopenia—Vinblastine—head and neck cancer	0.000738	0.00537	CcSEcCtD
Pomalidomide—Epistaxis—Fluorouracil—head and neck cancer	0.000732	0.00532	CcSEcCtD
Pomalidomide—Hyponatraemia—Docetaxel—head and neck cancer	0.000729	0.0053	CcSEcCtD
Pomalidomide—Pain in extremity—Docetaxel—head and neck cancer	0.000726	0.00528	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000712	0.00518	CcSEcCtD
Pomalidomide—Infection—Hydroxyurea—head and neck cancer	0.000683	0.00496	CcSEcCtD
Pomalidomide—Dehydration—Docetaxel—head and neck cancer	0.000676	0.00491	CcSEcCtD
Pomalidomide—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000674	0.0049	CcSEcCtD
Pomalidomide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000673	0.00489	CcSEcCtD
Pomalidomide—Skin disorder—Hydroxyurea—head and neck cancer	0.000668	0.00485	CcSEcCtD
Pomalidomide—Dry skin—Docetaxel—head and neck cancer	0.000666	0.00484	CcSEcCtD
Pomalidomide—Breast disorder—Docetaxel—head and neck cancer	0.000656	0.00477	CcSEcCtD
Pomalidomide—Decreased appetite—Vinblastine—head and neck cancer	0.000655	0.00476	CcSEcCtD
Pomalidomide—Nasopharyngitis—Docetaxel—head and neck cancer	0.00065	0.00472	CcSEcCtD
Pomalidomide—Pain—Vinblastine—head and neck cancer	0.000644	0.00469	CcSEcCtD
Pomalidomide—Constipation—Vinblastine—head and neck cancer	0.000644	0.00469	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000641	0.00466	CcSEcCtD
Pomalidomide—Feeling abnormal—Vinblastine—head and neck cancer	0.000621	0.00452	CcSEcCtD
Pomalidomide—Dyspnoea—Hydroxyurea—head and neck cancer	0.000613	0.00446	CcSEcCtD
Pomalidomide—Decreased appetite—Hydroxyurea—head and neck cancer	0.000597	0.00434	CcSEcCtD
Pomalidomide—Pancytopenia—Docetaxel—head and neck cancer	0.000596	0.00434	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000593	0.00431	CcSEcCtD
Pomalidomide—Fatigue—Hydroxyurea—head and neck cancer	0.000593	0.00431	CcSEcCtD
Pomalidomide—Constipation—Hydroxyurea—head and neck cancer	0.000588	0.00427	CcSEcCtD
Pomalidomide—Pain—Hydroxyurea—head and neck cancer	0.000588	0.00427	CcSEcCtD
Pomalidomide—Neutropenia—Docetaxel—head and neck cancer	0.000587	0.00427	CcSEcCtD
Pomalidomide—Weight increased—Docetaxel—head and neck cancer	0.000571	0.00415	CcSEcCtD
Pomalidomide—Weight decreased—Docetaxel—head and neck cancer	0.000568	0.00413	CcSEcCtD
Pomalidomide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000566	0.00412	CcSEcCtD
Pomalidomide—Pneumonia—Docetaxel—head and neck cancer	0.000563	0.00409	CcSEcCtD
Pomalidomide—Anaemia—Fluorouracil—head and neck cancer	0.00056	0.00407	CcSEcCtD
Pomalidomide—Infestation—Docetaxel—head and neck cancer	0.00056	0.00407	CcSEcCtD
Pomalidomide—Infestation NOS—Docetaxel—head and neck cancer	0.00056	0.00407	CcSEcCtD
Pomalidomide—Hypersensitivity—Vinblastine—head and neck cancer	0.000555	0.00404	CcSEcCtD
Pomalidomide—Renal failure—Docetaxel—head and neck cancer	0.00055	0.004	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000549	0.00399	CcSEcCtD
Pomalidomide—Body temperature increased—Hydroxyurea—head and neck cancer	0.000543	0.00395	CcSEcCtD
Pomalidomide—Leukopenia—Fluorouracil—head and neck cancer	0.000543	0.00395	CcSEcCtD
Pomalidomide—Asthenia—Vinblastine—head and neck cancer	0.000541	0.00393	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000529	0.00385	CcSEcCtD
Pomalidomide—Epistaxis—Docetaxel—head and neck cancer	0.000528	0.00384	CcSEcCtD
Pomalidomide—Diarrhoea—Vinblastine—head and neck cancer	0.000516	0.00375	CcSEcCtD
Pomalidomide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000506	0.00368	CcSEcCtD
Pomalidomide—Confusional state—Fluorouracil—head and neck cancer	0.000499	0.00363	CcSEcCtD
Pomalidomide—Dizziness—Vinblastine—head and neck cancer	0.000498	0.00362	CcSEcCtD
Pomalidomide—Urinary tract disorder—Docetaxel—head and neck cancer	0.000496	0.00361	CcSEcCtD
Pomalidomide—Oedema peripheral—Docetaxel—head and neck cancer	0.000495	0.0036	CcSEcCtD
Pomalidomide—Connective tissue disorder—Docetaxel—head and neck cancer	0.000494	0.00359	CcSEcCtD
Pomalidomide—Asthenia—Hydroxyurea—head and neck cancer	0.000493	0.00359	CcSEcCtD
Pomalidomide—Urethral disorder—Docetaxel—head and neck cancer	0.000493	0.00358	CcSEcCtD
Pomalidomide—Infection—Fluorouracil—head and neck cancer	0.000491	0.00357	CcSEcCtD
Pomalidomide—Nervous system disorder—Fluorouracil—head and neck cancer	0.000485	0.00353	CcSEcCtD
Pomalidomide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000484	0.00352	CcSEcCtD
Pomalidomide—Vomiting—Vinblastine—head and neck cancer	0.000479	0.00348	CcSEcCtD
Pomalidomide—Headache—Vinblastine—head and neck cancer	0.000472	0.00343	CcSEcCtD
Pomalidomide—Diarrhoea—Hydroxyurea—head and neck cancer	0.00047	0.00342	CcSEcCtD
Pomalidomide—Cardiac disorder—Docetaxel—head and neck cancer	0.000466	0.00339	CcSEcCtD
Pomalidomide—Angiopathy—Docetaxel—head and neck cancer	0.000456	0.00332	CcSEcCtD
Pomalidomide—Dizziness—Hydroxyurea—head and neck cancer	0.000454	0.0033	CcSEcCtD
Pomalidomide—Mediastinal disorder—Docetaxel—head and neck cancer	0.000453	0.00329	CcSEcCtD
Pomalidomide—Chills—Docetaxel—head and neck cancer	0.000451	0.00328	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000451	0.00328	CcSEcCtD
Pomalidomide—Nausea—Vinblastine—head and neck cancer	0.000448	0.00325	CcSEcCtD
Pomalidomide—Insomnia—Fluorouracil—head and neck cancer	0.000447	0.00325	CcSEcCtD
Pomalidomide—Dyspnoea—Fluorouracil—head and neck cancer	0.000441	0.00321	CcSEcCtD
Pomalidomide—Mental disorder—Docetaxel—head and neck cancer	0.00044	0.0032	CcSEcCtD
Pomalidomide—Malnutrition—Docetaxel—head and neck cancer	0.000437	0.00318	CcSEcCtD
Pomalidomide—Vomiting—Hydroxyurea—head and neck cancer	0.000437	0.00318	CcSEcCtD
Pomalidomide—Rash—Hydroxyurea—head and neck cancer	0.000433	0.00315	CcSEcCtD
Pomalidomide—Dermatitis—Hydroxyurea—head and neck cancer	0.000433	0.00315	CcSEcCtD
Pomalidomide—Headache—Hydroxyurea—head and neck cancer	0.000431	0.00313	CcSEcCtD
Pomalidomide—Decreased appetite—Fluorouracil—head and neck cancer	0.00043	0.00313	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000427	0.00311	CcSEcCtD
Pomalidomide—Back pain—Docetaxel—head and neck cancer	0.000423	0.00308	CcSEcCtD
Pomalidomide—Pain—Fluorouracil—head and neck cancer	0.000423	0.00308	CcSEcCtD
Pomalidomide—Muscle spasms—Docetaxel—head and neck cancer	0.000421	0.00306	CcSEcCtD
Pomalidomide—Nausea—Hydroxyurea—head and neck cancer	0.000408	0.00297	CcSEcCtD
Pomalidomide—Feeling abnormal—Fluorouracil—head and neck cancer	0.000408	0.00296	CcSEcCtD
Pomalidomide—Anaemia—Docetaxel—head and neck cancer	0.000404	0.00294	CcSEcCtD
Pomalidomide—Leukopenia—Docetaxel—head and neck cancer	0.000392	0.00285	CcSEcCtD
Pomalidomide—Body temperature increased—Fluorouracil—head and neck cancer	0.000391	0.00284	CcSEcCtD
Pomalidomide—Cough—Docetaxel—head and neck cancer	0.000382	0.00278	CcSEcCtD
Pomalidomide—Arthralgia—Docetaxel—head and neck cancer	0.000372	0.00271	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00037	0.00269	CcSEcCtD
Pomalidomide—Hypersensitivity—Fluorouracil—head and neck cancer	0.000364	0.00265	CcSEcCtD
Pomalidomide—Confusional state—Docetaxel—head and neck cancer	0.00036	0.00262	CcSEcCtD
Pomalidomide—Infection—Docetaxel—head and neck cancer	0.000355	0.00258	CcSEcCtD
Pomalidomide—Nervous system disorder—Docetaxel—head and neck cancer	0.00035	0.00255	CcSEcCtD
Pomalidomide—Pruritus—Fluorouracil—head and neck cancer	0.00035	0.00254	CcSEcCtD
Pomalidomide—Thrombocytopenia—Docetaxel—head and neck cancer	0.00035	0.00254	CcSEcCtD
Pomalidomide—Skin disorder—Docetaxel—head and neck cancer	0.000347	0.00252	CcSEcCtD
Pomalidomide—Diarrhoea—Fluorouracil—head and neck cancer	0.000338	0.00246	CcSEcCtD
Pomalidomide—Dizziness—Fluorouracil—head and neck cancer	0.000327	0.00238	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000325	0.00237	CcSEcCtD
Pomalidomide—Insomnia—Docetaxel—head and neck cancer	0.000323	0.00235	CcSEcCtD
Pomalidomide—Dyspnoea—Docetaxel—head and neck cancer	0.000318	0.00231	CcSEcCtD
Pomalidomide—Vomiting—Fluorouracil—head and neck cancer	0.000315	0.00229	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP8—head and neck cancer	0.000314	0.00297	CbGpPWpGaD
Pomalidomide—Rash—Fluorouracil—head and neck cancer	0.000312	0.00227	CcSEcCtD
Pomalidomide—Dermatitis—Fluorouracil—head and neck cancer	0.000312	0.00227	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MAPK3—head and neck cancer	0.000311	0.00294	CbGpPWpGaD
Pomalidomide—Decreased appetite—Docetaxel—head and neck cancer	0.00031	0.00226	CcSEcCtD
Pomalidomide—Headache—Fluorouracil—head and neck cancer	0.00031	0.00225	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL2—head and neck cancer	0.00031	0.00293	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—head and neck cancer	0.00031	0.00293	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—head and neck cancer	0.000309	0.00293	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000308	0.00224	CcSEcCtD
Pomalidomide—Fatigue—Docetaxel—head and neck cancer	0.000308	0.00224	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—STAT3—head and neck cancer	0.000306	0.0029	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—MAPK1—head and neck cancer	0.000306	0.00289	CbGpPWpGaD
Pomalidomide—Pain—Docetaxel—head and neck cancer	0.000305	0.00222	CcSEcCtD
Pomalidomide—Constipation—Docetaxel—head and neck cancer	0.000305	0.00222	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—GSTM1—head and neck cancer	0.000302	0.00286	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MAPK1—head and neck cancer	0.000296	0.0028	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Docetaxel—head and neck cancer	0.000294	0.00214	CcSEcCtD
Pomalidomide—Nausea—Fluorouracil—head and neck cancer	0.000294	0.00214	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—MAPK3—head and neck cancer	0.000292	0.00277	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—SOD2—head and neck cancer	0.000292	0.00277	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.00029	0.00275	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BCL2—head and neck cancer	0.00029	0.00274	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CASP8—head and neck cancer	0.000289	0.00274	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—MAPK3—head and neck cancer	0.000288	0.00273	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—MAPK1—head and neck cancer	0.000282	0.00267	CbGpPWpGaD
Pomalidomide—Body temperature increased—Docetaxel—head and neck cancer	0.000282	0.00205	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—CEBPA—head and neck cancer	0.000282	0.00267	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—GPX1—head and neck cancer	0.000279	0.00264	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—MAPK1—head and neck cancer	0.000274	0.00259	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—head and neck cancer	0.000268	0.00254	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—head and neck cancer	0.000266	0.00251	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000264	0.0025	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Docetaxel—head and neck cancer	0.000263	0.00191	CcSEcCtD
Pomalidomide—CYP1A2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000263	0.00248	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.000263	0.00248	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.000263	0.00248	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—head and neck cancer	0.000257	0.00243	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000256	0.00243	CbGpPWpGaD
Pomalidomide—Asthenia—Docetaxel—head and neck cancer	0.000256	0.00186	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	0.000254	0.0024	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BCL2L1—head and neck cancer	0.000253	0.0024	CbGpPWpGaD
Pomalidomide—Pruritus—Docetaxel—head and neck cancer	0.000253	0.00184	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—MAPK3—head and neck cancer	0.000249	0.00236	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—STAT3—head and neck cancer	0.000249	0.00235	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000248	0.00235	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000246	0.00232	CbGpPWpGaD
Pomalidomide—Diarrhoea—Docetaxel—head and neck cancer	0.000244	0.00178	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—AKT1—head and neck cancer	0.000241	0.00228	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—head and neck cancer	0.000239	0.00226	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—MAPK1—head and neck cancer	0.000237	0.00224	CbGpPWpGaD
Pomalidomide—Dizziness—Docetaxel—head and neck cancer	0.000236	0.00172	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—VEGFA—head and neck cancer	0.000228	0.00216	CbGpPWpGaD
Pomalidomide—Vomiting—Docetaxel—head and neck cancer	0.000227	0.00165	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CASP8—head and neck cancer	0.000226	0.00214	CbGpPWpGaD
Pomalidomide—Rash—Docetaxel—head and neck cancer	0.000225	0.00164	CcSEcCtD
Pomalidomide—Dermatitis—Docetaxel—head and neck cancer	0.000225	0.00164	CcSEcCtD
Pomalidomide—Headache—Docetaxel—head and neck cancer	0.000224	0.00163	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—HRAS—head and neck cancer	0.000223	0.00211	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000217	0.00206	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—AKT1—head and neck cancer	0.000217	0.00205	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—MAPK3—head and neck cancer	0.000216	0.00204	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—head and neck cancer	0.000215	0.00203	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000212	0.00201	CbGpPWpGaD
Pomalidomide—Nausea—Docetaxel—head and neck cancer	0.000212	0.00154	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—head and neck cancer	0.00021	0.00199	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—head and neck cancer	0.00021	0.00198	CbGpPWpGaD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00021	0.00198	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP8—head and neck cancer	0.000207	0.00196	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000206	0.00195	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—MAPK3—head and neck cancer	0.000205	0.00194	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—MAPK1—head and neck cancer	0.000205	0.00194	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CDH1—head and neck cancer	0.000205	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—head and neck cancer	0.000204	0.00193	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000203	0.00192	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—head and neck cancer	0.0002	0.00189	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—head and neck cancer	0.000199	0.00188	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000196	0.00185	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000196	0.00185	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—MAPK1—head and neck cancer	0.000195	0.00185	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—NAT2—head and neck cancer	0.000195	0.00185	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—head and neck cancer	0.000195	0.00184	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—AKT1—head and neck cancer	0.000194	0.00184	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP8—head and neck cancer	0.000194	0.00184	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—NAT2—head and neck cancer	0.000193	0.00182	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—MAPK3—head and neck cancer	0.000191	0.00181	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—head and neck cancer	0.00019	0.0018	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CCND1—head and neck cancer	0.00019	0.0018	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—head and neck cancer	0.000189	0.00179	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000187	0.00177	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—MAPK1—head and neck cancer	0.000182	0.00172	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—BCL2—head and neck cancer	0.000179	0.0017	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BCL2—head and neck cancer	0.000178	0.00168	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—MAPK3—head and neck cancer	0.000176	0.00166	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000175	0.00166	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—head and neck cancer	0.000172	0.00163	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000172	0.00163	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—PIK3CA—head and neck cancer	0.00017	0.0016	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—MAPK1—head and neck cancer	0.000167	0.00158	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTM1—head and neck cancer	0.000165	0.00156	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—head and neck cancer	0.000164	0.00155	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000164	0.00155	CbGpPWpGaD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000162	0.00153	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000159	0.0015	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	0.000157	0.00149	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MAPK3—head and neck cancer	0.000156	0.00148	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	0.000156	0.00148	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP8—head and neck cancer	0.000156	0.00147	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CCND1—head and neck cancer	0.000154	0.00146	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—STAT3—head and neck cancer	0.000152	0.00143	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000151	0.00143	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.00015	0.00142	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MAPK1—head and neck cancer	0.000149	0.00141	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—head and neck cancer	0.000149	0.00141	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000149	0.00141	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000146	0.00138	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—HRAS—head and neck cancer	0.000146	0.00138	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—PIK3CA—head and neck cancer	0.000145	0.00137	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000145	0.00137	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000143	0.00135	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—UROD—head and neck cancer	0.000142	0.00134	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—head and neck cancer	0.000139	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—head and neck cancer	0.000139	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—MAPK3—head and neck cancer	0.000137	0.0013	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000133	0.00126	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000132	0.00125	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—MAPK1—head and neck cancer	0.000131	0.00124	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	0.000129	0.00122	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—AKT1—head and neck cancer	0.000129	0.00122	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—head and neck cancer	0.000125	0.00118	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000125	0.00118	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000123	0.00116	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—head and neck cancer	0.00012	0.00114	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—head and neck cancer	0.000119	0.00112	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MAPK3—head and neck cancer	0.000118	0.00112	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—head and neck cancer	0.000118	0.00111	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—head and neck cancer	0.000117	0.00111	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	0.000115	0.00109	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—PIK3CA—head and neck cancer	0.000113	0.00107	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000113	0.00107	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	0.000113	0.00106	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000112	0.00106	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MAPK1—head and neck cancer	0.000112	0.00106	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—head and neck cancer	0.000112	0.00106	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000111	0.00105	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000111	0.00105	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.000111	0.00105	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.00011	0.00104	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000108	0.00103	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	0.000106	0.00101	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	0.000101	0.000958	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	0.000101	0.000958	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—UROD—head and neck cancer	0.000101	0.000953	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—head and neck cancer	0.0001	0.000951	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	0.0001	0.000946	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—head and neck cancer	9.7e-05	0.000918	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MAPK3—head and neck cancer	9.68e-05	0.000916	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	9.64e-05	0.000912	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	9.51e-05	0.0009	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—head and neck cancer	9.42e-05	0.000891	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	9.3e-05	0.00088	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—head and neck cancer	9.26e-05	0.000876	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MAPK1—head and neck cancer	9.21e-05	0.000871	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—head and neck cancer	9.21e-05	0.000871	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	9.14e-05	0.000865	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	9.02e-05	0.000853	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NOTCH1—head and neck cancer	9e-05	0.000851	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	8.89e-05	0.000841	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	8.79e-05	0.000831	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	8.5e-05	0.000804	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—head and neck cancer	8.49e-05	0.000803	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—UROD—head and neck cancer	8.04e-05	0.000761	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	7.98e-05	0.000755	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—head and neck cancer	7.96e-05	0.000753	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—head and neck cancer	7.73e-05	0.000731	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	7.71e-05	0.000729	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	7.68e-05	0.000727	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	7.44e-05	0.000704	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	7.37e-05	0.000697	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	7.34e-05	0.000694	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	7.18e-05	0.000679	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	7.06e-05	0.000667	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	6.96e-05	0.000658	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	6.96e-05	0.000658	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	6.59e-05	0.000624	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	6.58e-05	0.000623	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	6.27e-05	0.000593	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	6.26e-05	0.000593	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.26e-05	0.000592	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	6.26e-05	0.000592	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.24e-05	0.00059	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—UROD—head and neck cancer	6.21e-05	0.000587	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	6.2e-05	0.000587	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NAT2—head and neck cancer	5.9e-05	0.000558	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	5.66e-05	0.000535	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	5.46e-05	0.000517	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	5.44e-05	0.000514	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—head and neck cancer	5.26e-05	0.000498	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	5.26e-05	0.000497	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—head and neck cancer	5.21e-05	0.000493	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—DPYD—head and neck cancer	5.17e-05	0.00049	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK3—head and neck cancer	4.98e-05	0.000471	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	4.93e-05	0.000467	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—YAP1—head and neck cancer	4.91e-05	0.000465	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK1—head and neck cancer	4.74e-05	0.000448	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—head and neck cancer	4.73e-05	0.000448	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	4.67e-05	0.000441	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	4.44e-05	0.00042	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.44e-05	0.00042	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.44e-05	0.00042	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NAT2—head and neck cancer	4.18e-05	0.000396	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	3.85e-05	0.000365	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—head and neck cancer	3.8e-05	0.00036	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.73e-05	0.000353	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—DPYD—head and neck cancer	3.67e-05	0.000347	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.55e-05	0.000335	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.51e-05	0.000332	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—YAP1—head and neck cancer	3.48e-05	0.000329	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—head and neck cancer	3.36e-05	0.000318	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAT2—head and neck cancer	3.34e-05	0.000316	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.22e-05	0.000304	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.15e-05	0.000298	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMS—head and neck cancer	2.95e-05	0.000279	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—DPYD—head and neck cancer	2.93e-05	0.000277	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—head and neck cancer	2.91e-05	0.000276	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPX1—head and neck cancer	2.79e-05	0.000264	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—YAP1—head and neck cancer	2.78e-05	0.000263	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1A1—head and neck cancer	2.76e-05	0.000261	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOTCH1—head and neck cancer	2.64e-05	0.00025	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAT2—head and neck cancer	2.58e-05	0.000244	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.27e-05	0.000215	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—DPYD—head and neck cancer	2.26e-05	0.000214	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—YAP1—head and neck cancer	2.14e-05	0.000203	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMS—head and neck cancer	2.09e-05	0.000198	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.09e-05	0.000198	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—head and neck cancer	2.07e-05	0.000195	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPX1—head and neck cancer	1.98e-05	0.000187	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1A1—head and neck cancer	1.96e-05	0.000185	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.82e-05	0.000172	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—head and neck cancer	1.71e-05	0.000162	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMS—head and neck cancer	1.67e-05	0.000158	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.65e-05	0.000156	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPX1—head and neck cancer	1.58e-05	0.000149	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.56e-05	0.000148	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—head and neck cancer	1.53e-05	0.000145	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK3—head and neck cancer	1.46e-05	0.000138	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—head and neck cancer	1.43e-05	0.000136	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK1—head and neck cancer	1.39e-05	0.000132	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—head and neck cancer	1.39e-05	0.000132	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMS—head and neck cancer	1.29e-05	0.000122	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.28e-05	0.000122	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.27e-05	0.00012	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPX1—head and neck cancer	1.22e-05	0.000115	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—head and neck cancer	1.21e-05	0.000114	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.21e-05	0.000114	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—head and neck cancer	1.16e-05	0.00011	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—head and neck cancer	1.12e-05	0.000106	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—head and neck cancer	1.02e-05	9.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—head and neck cancer	1.01e-05	9.56e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—head and neck cancer	9.86e-06	9.33e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—head and neck cancer	9.3e-06	8.8e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—head and neck cancer	8.26e-06	7.81e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—head and neck cancer	8.11e-06	7.67e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—head and neck cancer	7.18e-06	6.79e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—head and neck cancer	7.17e-06	6.78e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—head and neck cancer	6.26e-06	5.92e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—head and neck cancer	5.85e-06	5.54e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—head and neck cancer	5.72e-06	5.41e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—head and neck cancer	4.67e-06	4.42e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.41e-06	4.18e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—head and neck cancer	3.61e-06	3.41e-05	CbGpPWpGaD
